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Abstract		Gene	therapy	is	currently	an	irreversible	approach,	without	possibilities	to	fine-tune	or	halt	 the	 expression	 of	 a	 therapeutic	 gene	 product.	 Especially	 when	 expressing	neurotrophic	factors	to	treat	neurodegenerative	disorders,	options	to	regulate	transgene	expression	 levels	might	 be	 beneficial.	We	 thus	 developed	 an	 advanced	 single-genome	inducible	 AAV	 vector	 for	 expression	 of	 GDNF,	 under	 control	 of	 the	 approved	 small	molecule	drug	mifepristone.	In	the	rat	brain,	GDNF	expression	can	be	induced	over	a	wide	range	up	to	three	hundred-fold	over	endogenous	background,	and	completely	returns	to	baseline	within	3-4	weeks.	When	applied	with	appropriate	serotype	and	titre,	the	vector	is	 absolutely	 free	 of	 any	 non-induced	 background	 expression.	 In	 the	BACHD	model	 of	Huntington´s	disease	we	demonstrate	that	the	vector	can	be	kept	in	a	continuous	ON-state	for	 extended	 periods	 of	 time.	 In	 a	model	 of	 Parkinson´s	 disease	we	 demonstrate	 that	repeated	short-term	expression	of	GDNF	restores	motor	capabilities	in	6-OHDA-lesioned	rats.	We	also	report	on	sex-dependent	pharmacodynamics	of	mifepristone	in	the	rodent	brain.	Taken	together,	we	show	that	wide-range	and	high-level	induction,	background-free,	fully	reversible	and	therapeutically	active	GDNF	expression	can	be	achieved	under	tight	pharmacological	control	by	this	novel	AAV	-	“Gene	Switch”	vector.			
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Introduction	Gene	 therapy	 in	 its	 current	 layout	 is	 an	 irreversible	 treatment:	 a	 curative	 gene	 is	introduced	into	patient´s	tissues	by	means	of	a	viral	or	non-viral	vector	and	produces	its	gene	product	(a	protein	or	regulatory	nucleic	acid)	from	the	time	of	vector	application	onward.	 In	 case	 of	 unwanted	 side	 effects	 or	 sufficient	 therapeutic	 success,	 transgene	expression	cannot	be	stopped	nor	can	the	level	of	expression	be	modified	according	to	individual	patient´s	needs.				Thus,	gene	therapy	systems	allowing	for	external	control	over	the	expressed	transgene	by	 pharmacological	 means	 would	 be	 highly	 beneficial	 under	 certain	 circumstances.	Several	such	gene	transfer	systems	are	available,	and	especially	tetracycline-controlled	gene	expression	has	been	developed	into	very	advanced	systems	1,	but	none	has	advanced	into	 clinical	 applicability	 yet	 2.	 This	 unfortunate	 fact	 at	 least	 partially	 depends	 on	 the	finding	that	the	bacteria-derived	Tet-operator	provoked	substantial	immune	responses	when	exploited	 in	non-human	primate	muscle,	 although	 it	worked	almost	perfectly	 in	immune	restricted	compartments	like	the	retina	3-5.	Another	highly	promising	inducible	gene	 therapy	 concept,	 based	 solely	 on	 human	 components	 and	 thereby	 by	 default	preventing	immune	issues,	did	not	advance	to	application	in	patients	due	to	unavailability	of	 clinically	 approved	 analogues	 to	 its	 small	 molecule	 drug,	 rapamycin,	 a	 strong	immunosuppressant	 6.	 Furthermore,	 rapamycin	 crosses	 the	 blood-brain-barrier	inefficiently,	 requiring	 clinically	 non-acceptable	 dosages	 for	 regulation	 of	 transgene	expression	in	the	brain	7.		In	order	to	drive	forward	development	of	alternative	regulated	gene	therapy	vectors,	we	recently	 adopted	 the	 “GeneSwitch”	 system	 to	 AAV	 vectors,	 where	 regulated	 GDNF	expression	 is	 under	 control	 of	 the	 clinically	 approved	 synthetic	 steroid	 mifepristone	(Mfp)	 8,	 9.	 	 In	 this	 system,	 Mfp	 application	 activates	 the	 GeneSwitch	 (GS)	 protein	 by	dimerization,	resulting	in	transgene	expression	from	the	responsive	minimal	UAS-TATA	promoter	10.	GS	is	a	fusion	of	a	short	fragment	of	the	yeast	Gal4-DNA	binding	domain	with	a	truncated	human	progesterone	receptor	and	the	human	p65	transactivator.	As	it	does	not	contain	bacterial	or	viral	components,	it	is	anticipated	to	be	less	immunogenic	than	the	Tet	repressor	and	thus	might	become	clinically	exploitable.	Our	earlier	adaptions	of	the	GS	system	to	AAV	vectors	had	to	rely	on	a	dual	vector	layout	in	order	to	achieve	relatively	low	background	expression	of	GDNF.	Furthermore,	the	rate	of	induction	of	GDNF	expression	was	only	moderate,	and	the	promoters	used	to	drive	GS	expression	were	active	in	both	neurons	and	glia.	Here	we	show	that	an	advanced	single	
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vector	design	allowed	for	high-level	GDNF	induction	in	the	absence	of	any	non-induced	background	expression.	We	also	demonstrate	a	very	good	dose	response	for	this	system	in	the	rat	brain,	allowing	us	to	achieve	a	wide	variety	of	GDNF	levels	by	different	Mfp	dosing	regimens.	Importantly,	we	found	gender-specific	pharmacodynamics	of	Mfp	in	the	rat	 brain.	 We	 further	 demonstrate	 that	 the	 vector	 can	 be	 kept	 in	 the	 ON-state	 for	prolonged	periods	of	time	and	shows	biological	effects	in	a	mouse	model	of	Huntington´s	disease.	Finally,	we	show	that	in	an	established	rat	model	of	Parkinson´s	disease	GDNF	expression	from	this	AAV-GS-GDNF	vector	restored	motor	capabilities.					
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Results	
Design	of	a	single-vector	layout	for	Mfp-induced	GDNF	expression	It	was	the	first	aim	of	our	present	study	to	design	an	improved	vector	layout	allowing	for	incorporation	of	all	necessary	elements	into	a	single	AAV	vector	genome,	with	high	rate	of	induction	and	without	any	detectable	background	expression	in	absence	of	Mfp.	Figure	1A	 shows	 some	 of	 the	 iteratively	 tested	 vector	 constructs,	 differing	 mainly	 in	 the	orientation	 of	 the	 two	 expression	 cassettes	 to	 each	 other.	 In	 all	 these	 constructs	 GS	expression	 is	 driven	 by	 the	 strictly	 neuron-specific	 human	 synapsin	 1	 gene	 (hSyn)	promoter	11.	Vectors	were	evaluated	for	GDNF	expression	in	absence	and	presence	of	the	inducer	Mfp,	by	injecting	the	respective	recombinant	AAV-5	viruses	unilaterally	into	the	striatum,	application	of	Mfp	or	solvent	at	3	weeks	after	vector	injection,	and	collection	of	striatal	tissue	for	GDNF-ELISA	at	7	days	after	the	first	Mfp	application	(Figure	1B).	Levels	of	GDNF	achieved	by	the	various	vectors	are	shown	in	Figure	1C.		These	 experiments	 demonstrated,	 that	 in	 case	 of	 a	 head-to-head	 orientation	 of	 GS	 to	GDNF	expression	cassettes,	i.e.	when	hSyn	and	inducible	promoter	are	directly	side-by-side,	background	expression	of	GDNF	in	absence	of	Mfp	was	not	significantly	lower	than	GDNF	expression	after	 induction	by	Mfp:	 the	GS-GDNF-HtH	construct	expressed	650	±	192	 pg	GDNF/mg	 tissue	 in	 absence	 of	Mfp,	 and	 1094	±	 879	 pg	GDNF/mg	 tissue	 after	induction	by	Mfp.	Isolation	of	both	promoters	from	each	other	by	incorporation	of	one	or	three	 synthetic	 transcription	 blocker	 sequences	 reduced	 background	 expression	somewhat,	allowing	for	a	roughly	10-fold	induction	of	GDNF	expression:		the	GS-GDNF-HtH-TB	construct	expressed	174	±	25	pg	GDNF/mg	tissue	in	absence	of	Mfp,	and	868	±	552	pg	GDNF/mg	tissue	after	induction	by	Mfp.		However,	non-induced	GDNF	levels	were	still	about	30-fold	higher	as	compared	to	5-6	pg	GDNF/mg	tissue	in	non-treated	control	brains,	 or	 in	 brains	 injected	 with	 a	 GS-EGFP	 vector	 in	 absence	 or	 presence	 of	 Mfp	(construct	GS-EGFP-HtT	in	figure	1A).		This	situation	changed	completely	by	flipping	the	GS	expression	cassette	around,	so	that	GS	and	GDNF	were	in	a	head-to-tail	configuration	(construct	GS-GDNF-HtT	in	figure	1A).	Now,	 non-induced	 GDNF	 levels	were	 found	 to	 be	 at	 10	 ±	 4	 pg/mg	 tissue,	 while	Mfp-induced	GDNF	levels	reached	1942	±	793	pg/mg	tissue,	i.e.	an	almost	200-fold	induction	above	 non-induced	 background	 and	 almost	 400-fold	 above	 endogenous	 background	levels.	Induced	levels	of	GDNF	achieved	by	the	novel	one-vector	construct	were	at	least	in	the	 same	 order	 of	 magnitude	 as	 from	 a	 constitutive	 vector	 designed	 for	 maximum	expression.	 They	were	 also	 about	 one	 order	 of	magnitude	 higher	 than	 those	 recently	
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achieved	by	the	best	suited	two-vector	approach	8,	9.		All	these	experiments	were	carried	out	with	a	vector	titre	of	3x109	vg	/	striatum.		
Fine-tuning:	influences	of	AAV	titre	and	serotype	Given	the	significant	background	expression	seen	with	certain	constructs,	we	next	sought	to	establish	Mfp-induced	GDNF	expression,	which	is	absolutely	free	from	any	leaky,	non-induced	GDNF	production,	meaning	that	without	Mfp	application	only	the	endogenous	5-6	pg	GDNF	per	mg	of	striatal	 tissue	are	detectable.	To	achieve	this,	we	tested	titres	of	1x109	and	3x109	vg	of	AAV-5-GS-GDNF	and	AAV-1/2	GS-GDNF	vectors,	both	in	the	head-to-tail	(HtT)	configuration,	which	was	used	in	all	following	experiments.	The	mosaic	AAV-1/2	serotype	was	chosen	as	an	alternative	to	AAV-5,	as	this	serotype	allows	for	similar	tissue	 penetrance	 as	 AAV-5,	 but	 uses	 different	 primary	 receptors	 and	 is	 purified	 by	heparin	 affinity	 chromatography,	 while	 AAV-5	 was	 purified	 by	 AVB	 sepharose	chromatography.	These	experiments	should	also	allow	for	a	correlation	between	vector	titre	and	GDNF	levels.		A	side-by-side	comparison	of	3x109	and	1x109	vg/striatum	of	AAV-5-GS-GDNF	revealed	that:	 i)	 at	7	days	after	Mfp	 induction	the	3-fold	higher	vector	titre	 resulted	 in	1.5-fold	increased	levels	of	GDNF	(1942	±	793	pg/mg	tissue	versus	1298	±	450	pg/mg	tissue,	p	<	0.05,	power	(1-ß	err	prob)	=	0.55);	ii)	at	28	days	after	Mfp	induction	GDNF	levels	have	declined	close	to	endogenous	background	with	both	3x109	and	1x109	vg/striatum,	but	were	still	higher	than	endogenous	GDNF	levels	(p	<	0.05;	power	(1-ß	err	prob)	=	0.6);	iii)	at	 7	 days	 non-induced	 GDNF	 levels	 were	 significantly	 higher	 than	 endogenous	background	with	3x109	vg/striatum	(10.4	±	4	pg/mg	tissue	versus	5.5	±	1	pg/mg	tissue;	p	<	0.01;	power	(1-ß	err	prob)	=	0.83),	but	after	application	of	1x109	vg/striatum	GDNF	levels	were	 indistinguishable	 from	background	 (5.3	±	1.6	pg/mg	 tissue	versus	5.5	±	1	pg/mg	tissue).	Thus,	with	minor	modifications	of	AAV-5	vector	titre,	we	achieved	a	260-fold	 induction	 of	 GDNF	 levels	 over	 endogenous	 background,	 while	 without	 Mfp	application	absolutely	no	GDNF	above	endogenous	background	was	detectable	(Fig	2A,	B).		Since	 in	 these	 animal	 groups	 GDNF	 levels	 did	 not	 completely	 return	 to	 endogenous	background	levels	at	28	days	after	Mfp	application,	we	performed	another	animal	group	with	striatal	injection	of	1x109	vg	of	AAV-5-GS-GDNF,	and	followed	the	decay	of	GDNF	in	more	detail	and	over	longer	time	(Fig	2C).	These	results	demonstrate	that	GDNF	levels	drop	rapidly	after	withdrawal	of	Mfp	application,	and	completely	decay	to	endogenous	
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background	between	28	and	42	days	after	Mfp	application.	Thus,	the	novel	one-vector	GS-GDNF	system	proves	to	be	fully	reversible	in	terms	of	induction	of	GDNF	expression.				The	rate	of	induction	and	the	levels	of	non-induced	GDNF	levels	could	only	partially	be	repeated	with	the	same	vector	genome	packed	into	an	AAV-1/2	capsid,	indicating	that	the	choice	of	AAV	serotype	has	some	influence	on	the	performance	of	the	GeneSwitch	system	(Fig	2D).	An	AAV-1/2	vector	constitutively	expressing	GDNF	resulted	in	GDNF	levels	of	9917	±	3102	pg/mg	tissue,	which	is	significantly	more	GDNF	as	compared	to	5013	±	1102	pg/mg	tissue	achieved	with	an	AAV-5	at	the	same	titre	of	3x10e9	vg/striatum	(p	<	0.001;	power	(1-ß	err	prob)	=	0.95).	Application	of	3x109	vg	of	AAV-1/2	GS-GDNF	resulted	in	1012	±	553	pg	GDNF/mg	tissue,	which	is	significantly	less	GDNF	as	compared	to	1942	±	793	pg/mg	tissue	achieved	with	the	equivalent	AAV-5	vector	(p	<	0.05;	power	(1-ß	err	prob)	=	0.65).	Strikingly,	reducing	the	titre	of	AAV-1/2-GS-GDNF	to	1x109	vg/striatum	achieved	only	1/10th	of	GDNF	as	 compared	 to	 the	equivalent	AAV-5	 (135	±	75	pg/mg	tissue	versus	1298	±	450	pg	GDNF/mg	tissue;	p	<	0.001;	power	(1-ß	err	prob)	=	1).		Furthermore,	 in	 absence	 of	 Mfp,	 background	 GDNF	 expression	 was	 moderately	 but	significantly	higher	with	any	titre	of	AAV-1/2-GS-GDNF	as	compared	to	the	corresponding	AAV-5	vector	(Fig	2D).	Thus,	 while	 on	 principle	 the	 one-vector	 GeneSwitch	 system	 reacted	 similarly	 in	 both	serotypes,	usage	of	AAV-5	allowed	for	higher	levels	of	induction	and	elimination	of	non-induced	background	expression.			
Dose-response	 analysis:	 dependence	 of	 Mfp-induced	 GDNF	 levels	 on	 dosage	 and	
application	route	So	 far,	 all	 experiments	 in	 this	 and	 our	 previous	 studies	 8,	 9	 have	 been	 carried	 out	 by	inducing	GDNF	expression	through	application	of	Mfp	intraperitoneally	(i.p.),	dissolved	in	DMSO.	Mfp	is	insoluble	in	aqueous	solutions;	therefore,	we	preferred	dissolving	Mfp	in	an	organic	 solvent	 over	 the	 suspension	 in	 an	 aqueous	 carrier.	 Furthermore,	 in	 order	 to	guarantee	for	sufficient	bioavailability	of	the	drug,	3	i.p.	injections	of	20	mg/kg	each	were	performed	 on	 three	 consecutive	 days,	 based	 on	 the	 fact	 that	 in	 rodents	 half-life	 and	bioavailability	 of	 Mfp	 is	 significantly	 reduced	 as	 compared	 to	 humans	 (T1/2	 rat	 =	 4h,	human	=	30h;	bioavailability	rat	=	39%,	human	=	69%	12.		We	 now	 aimed	 to	 determine	 if	 GDNF	 production	 from	 the	 new	 one-vector	 GS-GDNF	system	can	be	modulated	by	different	dosages	of	Mfp,	allowing	to	achieve	full	external	control	not	only	over	ON-OFF	states	but	also	for	gradual	changes	in	neurotrophin	levels	
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(Figure	3).	These	studies	revealed	a	favourable	dose-response	curve	for	Mfp	applied	3x	by	 the	 i.p.	 route,	 with	 dosages	 as	 low	 as	 1	 mg/kg	 already	 causing	 therapeutically	meaningful	levels	of	GDNF	of	about	155	±	52	pg/mg	striatal	tissue.	Application	of	only	a	single	dose	of	Mfp	resulted	in	proportionally	less	activation	of	the	system:	while	3x	20	mg/kg	Mfp	achieved	about	1600	±	500	pg	GDNF	per	mg	of	striatal	tissue,	1x	20	mg/kg	Mfp	achieved	540	±	247	pg	GDNF	per	mg	tissue.		These	 results	 were	 on	 principle	 confirmed	 by	 oral	 application	 of	 Mfp,	 which	 was	suspended	 in	 either	 an	 aqueous	 carrier	 including	micelle	 forming	 organic	 compounds	(ASV)	or	in	sesame	oil,	both	of	which	delivered	an	identical	outcome.	Oral	administration	required	higher	dosages	of	Mfp	to	achieve	similar	levels	of	GDNF	induction,	indicating	a	lower	bioavailability	of	the	drug	through	this	route.	Again,	a	single	oral	administration	of	Mfp	resulted	in	less	pronounced	GDNF	induction	as	compared	to	3x	Mfp	application:	3x	50	mg/kg	resulted	in	1010	±	260	pg	GDNF	per	mg	of	striatal	tissue,	while	1x	50	mg/kg	achieved	525	±	198	pg	GDNF	per	mg	of	striatal	tissue.		Overall,	using	different	routes	and	dosages	of	Mfp	application	allowed	for	a	wide	range	of	GDNF	 levels	 to	 be	 induced	 in	 rat	 brains,	 ranging	 from	 30-fold	 up	 to	 300-fold	 over	endogenous	levels.		
	
Mfp	pharmacodynamics	in	female	versus	male	rat	brain:	robust	differences	in	GDNF	
induction	All	experiments	in	this	and	our	previous	studies	have	been	performed	in	female	rats,	as	due	 to	 their	 reduced	 body	 weight	 gain	 they	 are	 easier	 to	 maintain	 and	 to	 handle	 as	compared	to	male	rats.	Unexpectedly,	we	found	a	limitation	of	Mfp	pharmacodynamics	in	male	rats,	with	significant	impact	on	therapeutic	applications:	as	shown	in	Fig.	4	A,	Mfp	applied	into	male	rats	resulted	in	roughly	8-fold	less	induction	of	striatal	GDNF	expression	as	compared	to	the	same	dose	in	female	rats	(20	mg/kg	i.p.,	or	50	mg/kg	oral,	applied	on	three	consecutive	days).		It	has	been	demonstrated	that	certain	AAV	vectors	have	different	transduction	properties	in	 male	 versus	 female	 animals,	 e.g.	 in	 liver	 or	 brain	 of	 rodents,	 in	 some	 cases	 even	independent	 from	 promoters	 and	 serotypes,	 in	 other	 cases	 depending	 on	 application	routes	13,	14	.	We	thus	injected	the	constitutively	expressing	AAV-5-syn-GDNF	vector	into	male	and	female	rat	brains	and	determined	GDNF	levels	obtained	in	both	genders	at	3	weeks	after	 injection.	This	experiment	 showed	 that	GDNF	levels	obtained	 in	male	and	female	striata	vary	by	no	more	than	5%	(males:	8446	±	2728	pg/mg	tissue;	females:	8176	
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±	3277	pg/mg	tissue;	n=7	per	group;	not	shown),	indicating	that	transduction	efficacy	of	AAV-5	 vectors	 is	 identical	 in	 male	 and	 female	 rat	 striatum.	 Thus,	 gender-specific	transduction	 is	 not	 responsible	 for	 the	 differences	 in	 GDNF	 induction	 after	 Mfp	application.				We	 thus	 determined	 plasma	 levels	 of	 Mfp	 in	 both	 genders	 after	 intraperitoneal	application	of	20	mg/kg	Mfp	each	on	three	consecutive	days.	As	shown	in	Fig.	4	C,	the	first	injection	resulted	in	identical	plasma	levels	of	Mfp	in	males	and	females	at	1	hour	after	Mfp	 injection.	 However,	 while	 the	 second	 application	 of	Mfp	 resulted	 in	 substantially	increased	levels	of	plasma	Mfp	in	female	rats	as	compared	to	the	first	injection,	this	was	not	true	for	male	rats,	and	likewise	the	third	injection	of	Mfp	did	not	raise	plasma	Mfp	levels	above	those	achieved	with	the	first	injection	in	male	rats.	As	a	consequence,	plasma	Mfp	levels	in	male	rats	were	robustly	lower	as	compared	to	females	over	the	course	of	the	application,	providing	the	basis	for	the	substantially	lower	rate	of	GDNF	induction	in	male	brains.	Given	that	in	female	rats	a	lowering	of	the	applied	Mfp	dosage	from	3x	20	mg/kg	to	3x	10	mg/kg	results	 in	a	4-fold	reduced	 induction	of	GDNF	in	the	brain	(Fig	3	B),	 it	seems	reasonable	to	argue	that	the	decreased	pharmacodynamic	action	of	Mfp	in	male	versus	 female	 rodent	brains	 is	directly	 correlated	 to	 its	 reduced	absorption,	 increased	clearance	or	sequestration	in	male	animals	as	compared	to	females.			
Sustained	 long-term	 term	 expression	 of	 GDNF	 in	 the	 Huntington´s	 disease	 BACHD	
mouse	model		Given	the	long	time	span	of	development	and	progression	of	neurodegenerative	disorders	in	man,	it	is	necessary	to	demonstrate	that	this	regulable	system	can	be	kept	in	the	ON-state	for	extended	periods	of	time.	This	issue	was	addressed	in	a	transgenic	animal	model	of	 Huntington´s	 disease,	 the	 BACHD	 mouse	 15.	 These	 mice	 develop	 a	 subtle	 striatal	pathology	 resembling	 human	 HD,	 but	 also	 gain	 significantly	 more	 weight	 than	 non-transgenic	littermates	due	to	expression	of	the	full-length	human	HTT	gene.	Reduction	of	weight	 gain	 (or	 even	 loss	 of	weight)	 is	 a	well-studied	 side-effect	 of	 continuous	GDNF	overexpression	16.	The	second	aim	of	this	trial	was	to	determine	if	GDNF	acts	as	a	potential	therapeutic	factor	in	this	model	of	HD.		At	2	months	of	age,	BACHD	mice	were	injected	bilaterally	into	striatum	with	3x109	vg	of	AAV-5-GS-GDNF,	AAV-5-GS-EGFP	or	AAV-5-syn-GDNF	(the	control	vector	constitutively	expressing	GDNF).	An	additional	group	was	injected	with	a	higher	titre	of	the	constitutive	GDNF	expressing	vector	(9x109	vg),	in	order	to	achieve	high	level	GDNF	expression.	This	
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group	was	 included	 into	 the	 study	 as	 neuroprotective	 effects	 of	 GDNF	 have	 not	 been	investigated	 in	 this	 model	 before,	 and	 it	 was	 unclear	 which	 GDNF	 levels	 might	 be	necessary	to	achieve	protective	effects.	Starting	 from	two	weeks	after	vector	 injection,	animals	were	given	a	single	i.p.	application	of	Mfp	in	sesame	oil	once	a	week	over	the	time	course	of	the	experiment	(dosage:	20	mg/kg).	Animals	were	subjected	to	weighing	every	week.	From	about	4	weeks	after	initiation	of	GDNF	expression	by	Mfp	onward,	animals	showed	 less	 weight	 gain	 as	 compared	 to	 animals	 injected	 with	 AAV-5-GS-GDNF	 but	treated	only	with	vehicle,	 or	 injected	with	AAV-5-GS-EGFP	and	 treated	with	Mfp.	This	reduction	in	weight	gain	was	similar	in	animals	expressing	GDNF	from	the	constitutive	vectors	(Fig	5	F)	or	from	the	GeneSwitch	vector	(Fig	5	G).		Mice	 were	 subjected	 to	 assessment	 of	 motor	 control	 capabilities	 on	 the	 accelerating	rotarod	at	9,	14,	27,	40	and	46	weeks	of	age.	These	experiments	demonstrated	a	positive	training	effect	 from	week	9	to	week	14	 for	all	groups	of	BACHD	mice,	except	 for	 those	animals	 that	were	 injected	with	 the	high	dose	of	 constitutively	expressing	AAV-5-syn-GDNF	(Fig.	5	H).	This	finding	suggests	that	at	least	early	in	disease	progression	high	doses	of	GDNF	might	rather	exert	negative	effects	on	motor	control	in	this	animal	model.	At	later	time	points,	animals	that	received	AAV-5-GS-GDNF	and	weekly	induction	by	Mfp	showed	a	tendency	to	perform	better	as	compared	to	AAV-5-GS-GDNF	animals	without	induction	or	AAV-5-GS-GDNF	controls	 (Fig	5	 I).	However,	despite	 the	 relatively	high	numbers	of	animals	per	group	(n	=	15	-	19)	statistical	analysis	by	ANCOVA	over	all	groups	and	time	points	 and	 taking	 into	 account	 the	 reduced	 weight	 gain	 of	 animals	 treated	 with	constitutive	or	induced	GDNF,	did	not	reveal	statistical	significant	improvements	of	motor	control	through	expression	of	GDNF.		After	sacrifice	at	10.5	months	of	age,	the	quantitative	analysis	of	striatal	sections	stained	with	dopamine-	and	cAMP-regulated	phosphoprotein	32	kDa	(DARPP-32),	a	GABAergic	marker	altered	in	HD	patients	17,	also	failed	to	reveal	a	neuroprotective	effect	of	GDNF	(not	 shown).	However,	 immunohistochemical	analysis	 for	GDNF	expression	confirmed	the	continuous	ON-state	of	the	GeneSwitch	system,	by	revealing	a	staining	level	of	similar	intensity	as	compared	to	GDNF	expression	from	the	constitutively	active	vectors	(Fig	5	B	-	E).		These	data	clearly	demonstrate	continuous	expression	of	physiologically	relevant	levels	of	GDNF	from	AAV-5-GS-GDNF	under	continuous	activation	by	Mfp.	Thus,	Mfp-induced	GDNF	expression	can	be	kept	“ON”	for	prolonged	periods	of	time.			
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Functional	test	of	AAV-5-GS-GDNF	in	the	partial	6-OHDA	model	of	Parkinson´s	disease	The	 vector	was	 further	 tested	 for	 therapeutic	 efficiency	 in	 the	 partial	 6-OHDA	 lesion	model	of	Parkinson´s	disease.	AAV-5	vectors	expressing	constitutive	GDNF	or	GS-GDNF	were	injected	into	the	lesioned	striata	at	3	weeks	after	6-OHDA	application	at	a	titre	of	1x109	vg.	Animals	were	subjected	to	apomorphine-induced	rotation	behaviour	before	6-OHDA	application	(timepoint	t=0),	and	at	2,	7,	10,	12,	15,	18,	21,	24,	27	and	31	weeks	after	lesion.	One	group	of	AAV-5-GS-GDNF	injected	animals	was	not	treated	with	Mfp,	a	second	group	was	given	Mfp	once	at	2	weeks	after	AAV	injection	(i.e.	at	5	weeks	after	6-OHDA	application),	and	a	third	group	received	Mfp	application	at	2,	7,12	and	17	weeks	after	AAV	injection	(i.e.	at	5,	10,	15	and	20	weeks	after	6-OHDA	application)	(Fig	6	A).	As	expected,	all	animals	lack	rotation	behaviour	before	6-OHDA	lesion,	and	showed	about	200	contralateral	turns	per	hour	at	2	weeks	after	lesion.	Animals	with	constitutive	GDNF	expression	returned	to	about	70	rotations/h	at	time	point	7	weeks	after	6-OHDA	lesion.	The	animals	of	 this	group	showed	a	tendency	 in	 increase	 in	rotations	up	to	about	100	rotations/h	 over	 the	 time	 course	 of	 the	 experiment,	 although	 this	 effect	 was	 not	statistically	significant.		Animals	injected	with	AAV-5-GS-GDNF	that	were	not	induced	with	Mfp	remained	at	200	rotations/h	 over	 the	 time	 course	 of	 the	 experiment,	 demonstrating	 absence	 of	 any	endogenous	recovery	or	leaky	GDNF	expression	at	biologically	relevant	levels.	Animals	induced	only	once	by	Mfp	showed	a	decline	from	200	rotations/h	at	time	point	7	weeks	after	 6-OHDA	 to	 about	 110	 rotations/h	 at	 time	 point	 10	 weeks	 after	 6-OHDA.	 These	animals	also	showed	a	moderate	 increase	 in	 rotation	behaviour	 from	about	12	weeks	after	6-OHDA	lesion	onward	(i.e.	at	7	weeks	after	induction	of	GDNF	expression),	which	became	significantly	different	from	rotations	at	7	weeks	after	6-OHDA	at	the	endpoint	of	the	 experiment	 at	 31	 weeks	 (i.e.	 at	 26	 weeks	 after	 the	 single	 induction	 of	 GDNF	expression).		Animals	that	received	4	inductions	of	GDNF	expression	at	intervals	of	roughly	4	weeks	showed	the	same	initial	decline	of	numbers	of	rotations	as	compared	to	animals	with	only	one	induction.	In	contrast	to	the	group	with	only	one	induction	the	numbers	of	rotations	in	the	four	times	induced	group	showed	stable	rotation	behaviour	over	the	time	course	of	the	 experiment.	 Comparing	 rotation	 behaviour	 between	 1x	 and	 4x	 induced	 animals	clearly	 demonstrated	 significantly	 fewer	 rotations	 for	 the	 4x	 induced	 animals	 at	 time	points	later	than	12	weeks	after	6-OHDA	lesion.	Notably,	rotation	behaviour	of	animals	
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injected	with	AAV-GS-GDNF,	which	were	repeatedly	induced	by	Mfp,	was	not	significantly	different	from	that	of	animals	expressing	GDNF	constitutively.		Animals	 of	 all	 groups	were	monitored	 for	weight	 gain,	 and,	 when	 analysed	 by	 2-way	ANOVA,	 failed	 to	 demonstrate	 significant	 differences	 between	 groups.	 However,	 it	appears	 noteworthy	 that	 animals	under	 constitutive	GDNF	 expression	presented	with	about	10%	 less	body	weight	at	 all	 time	points	after	vector	 injection,	 suggesting	 that	 a	subtle	negative	effect	of	GDNF	on	body	weight	might	be	present	in	this	group	(Suppl.	Fig.	1).	Analysis	of	rotation	behaviour	was	stopped	at	31	weeks	after	6-OHDA	lesion,	as	due	to	some	loss	of	experimental	animals	numbers	in	some	groups	had	dropped	to	only	5	rats.	All	remaining	animals	were	thus	used	for	two	purposes:	firstly,	we	aimed	to	prove	that	the	 AAV-5-GS-GDNF	 vector	 can	 be	 reactivated	 even	 after	 long-term	 inactivity,	 and	secondly,	 we	 quantified	 levels	 of	 dopamine	 (DA)	 and	 its	 metabolites,	 3,4-dihydroxyphenylacetic	 acid	 (DOPAC)	 and	 homovanillic	 acid	 (HVA)	 in	 striata	 of	 all	animals.	To	demonstrate	reactivation	of	the	system,	we	applied	Mfp	at	week	45	after	6-OHDA	 lesion,	 in	 the	group	of	 animals	 that	had	already	 received	4	 inductions	of	GDNF	expression	 at	 weeks	 5,	 10,	 15	 and	 20	 after	 6-OHDA	 lesion.	 Thus,	 the	 system	 was	reactivated	after	about	6	months	of	inactivity,	in	rats	that	have	reached	an	age	of	about	12	months.	As	shown	in	Fig	6	C,	this	reactivation	resulted	in	GDNF	expression	at	a	level	of	about	 10.000	 pg/mg	 tissue	 in	 the	 ipsilateral	 striatum,	 and	 significant	 leakage	 to	 the	contralateral	striatum.	The	level	of	GDNF	expression	obtained	in	these	brains	is	roughly	8-fold	higher	as	 compared	 to	 levels	obtained	 in	 rats	with	an	age	of	 about	2-3	months,	although	the	same	dosage	of	20	mg/kg	Mfp,	applied	on	three	consecutive	days,	was	used.	This	result	suggests	that	pharmacodynamics	of	Mfp	do	not	only	depend	on	the	gender	of	the	experimental	animals,	but	also	on	their	age.	Furthermore,	our	results	show	that	 in	animals	that	were	not	re-induced	or	did	not	receive	any	Mfp	throughout	the	course	of	the	study,	GDNF	levels	did	not	differ	from	endogenous	control	levels,	demonstrating	that	the	system	stays	absolutely	background-free	for	extended	periods	of	time	when	not	activated	by	Mfp.	In	order	to	relate	the	behavioural	assessment	of	motor	capabilities	to	molecular	data,	we	also	determined	levels	of	DA,	DOPAC	and	HVA	in	the	striata	of	all	animals	(Fig	6	D).	We	found	that	after	constitutive	GDNF	expression	levels	of	DA	were	not	significantly	different	from	contralateral	controls.	In	the	group	that	had	received	only	one	induction	of	GDNF	expression	DA	levels	were	equal	to	those	in	animals	that	had	not	received	any	induction	of	GDNF	expression.	DA	levels	of	animals	that	were	repeatedly	induced	to	express	GDNF	
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were	significantly	higher	than	those	that	were	not	induced,	but	also	significantly	lower	than	those	obtained	by	consecutive	GDNF	expression.	Thus,	the	assessment	of	available	dopamine	 reflects	 the	 results	 obtained	 by	 apomorphine-induced	 rotation	 analysis.	 It	needs	to	be	noted,	however,	that	rotation	behaviour	was	recorded	only	until	week	31	after	6-OHDA	lesion,	but	DA	and	metabolites	were	determined	at	week	46	after	6-OHDA	lesion.		
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Discussion:	
Is	there	a	need	for	a	regulated	GDNF	gene	therapy	vector?	Finding	the	optimal	dosage	is	a	key	requisite	for	successful	application	of	any	drug,	and	genetic	medicines	are	no	exception.	So	far,	this	can	only	be	achieved	by	varying	the	number	 of	 viral	 particles	 used	 for	 injection	 into	 patients.	 Thus,	 ability	 to	 regulate	 the	dosage	of	the	therapeutic	gene	product	through	external	pharmacological	controls	might	facilitate	dose-escalation	studies	considerably,	as	this	dosage	modification	can	be	tailored	according	to	responses	of	individual	patients.	Given	the	enormous	variability	in	clinical	phenotypes	 seen	 with	 PD	 18,	 an	 individual	 dosage	 regime	 for	 neurotrophic	 factor	expression	may	be	highly	beneficial.	Ageing-related	neurodegenerative	diseases	like	PD	and	 Alzheimer´s	 disease	 (AD)	 are	 multifactorial	 in	 etiology	 and	 multifaceted	 in	progression	of	pathology.	Mono-causal	 treatment	opportunities	are	unlikely	 to	emerge	soon,	 or	 may	 even	 not	 become	 available	 at	 all.	 Thus,	 neurotrophic	 factors	 as	“symptomatic”	treatment	options,	aiming	to	enhance	neuronal	survival	capabilities	and,	if	applied	early	enough,	enabling	restorative	attempts	of	the	lesioned	CNS,	are	still	valid	candidates	for	gene	therapy	approaches	targeting	these	devastating	disorders	19.	In	case	of	PD,	gaining	control	over	expression	levels	of	neurotrophic	factors	might	help	to	make	such	therapies	acceptable	for	patients	very	early	after	diagnosis,	at	times	when	effective	medication	is	available	in	form	of	L-DOPA.	These	patients	benefit	from	conventional	L-DOPA	 substitution	 therapy	 for	 a	 few	 years,	 but	 it	 appears	 that	 during	 this	 time	 their	dopaminergic	 output	 into	 caudate/putamen	 ceases	 completely,	 leaving	 little	 to	 no	template	 for	 any	 restoration	 of	 the	 dopaminergic	 projection	 20.	 Thus,	 availability	 of	 a	pharmacologically	controllable	gene	therapy	system	might	encourage	patients	to	accept	a	neurotrophic	 factor	gene	 therapy	at	 times	when	 it	has	still	 a	 good	chance	 to	 lead	 to	protective	and	probably	 restorative	effects,	because	 it	offers	a	distinct	 level	of	 control	over	an	otherwise	irreversible	and	non-controllable	therapeutic	approach.				
Functional	verification	of	Mfp-regulated	GDNF	expression	in	BACHD	mice	The	 new	 AAV-5-GS-GDNF	 vector	 was	 functionally	 tested	 in	 two	 different	 paradigms,	transgenic	BACHD	mice	and	6-OHDA	lesioned	rats.	BACHD	mice	are	a	slowly	progressive	model	of	Huntington’s	disease	(HD),	 that	show	low	to	moderate	HD-related	pathology,	accompanied	by	robust	increase	in	weight	gain	as	compared	to	non-transgenic	littermates	21.		A	major	side-effect	of	continuous	nigro-striatal	GDNF	overexpression	is	weight	loss	or	at	least	diminished	weight	gain	due	to	stimulation	of	corticotrophin	releasing	hormone	
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(CRH)	release	from	a	subgroup	of	hypothalamic	neurons	16,	22.	This	issue	was	exploited	to	demonstrate	that	the	GS-GDNF	system	can	be	kept	in	activated	ON-state	for	prolonged	times:	continuous	weight	recording	served	as	a	live	monitoring	system	for	the	presence	of	this	side-effect	of	GDNF.	The	reduction	of	weight	gain	in	BACHD	mice	that	was	achieved	with	Mfp-activated	GS-GDNF	was	indistinguishable	from	constitutive	GDNF	expression.	Thus,	a	weekly	application	of	Mfp	allowed	for	continuous	biological	effects	of	GDNF	over	a	period	of	over	7	months.	Although	we	had	not	determined	GDNF	levels	during	different	time	points	of	this	study,	our	results	strongly	suggest	that	no	evident	saturation	effects	due	to	repeated	Mfp	application	might	impact	on	long-term	GDNF	expression	from	this	vector.	Therapeutic	effects	of	GDNF	in	mouse	models	of	HD	have	been	shown	to	crucially	depend	on	the	respective	model	under	investigation:	GDNF	demonstrated	neuroprotective	effects	in	toxin-based	models	23,	24,	in	N171-82Q	mice	25,	26,	but	not	in	R6/2	mice	27.		Given	this	discrepancy,	it	would	thus	be	informative	to	know	if	GDNF	could	achieve	any	protective	or	restorative	effects	in	BACHD	mice,	which	are	clinically	relevant	due	to	their	expression	of	full	length	mutant	HTT	protein.	While	the	robust	impact	of	GDNF	on	body	weight	of	BACHD	mice	presented	a	serious	confounding	effect	on	the	subtle	improvements	seen	in	rotarod	 analysis,	 no	 therapeutic	 effect	 of	 GDNF	beyond	 that	 on	 body	weight	 could	 be	found	 in	this	model	of	HD.	Given	the	 fact	 that	high	 level	constitutive	GDNF	expression	initially	 had	 rather	 negative	 effects	 on	motor	 performance	 might	 be	 interpreted	 as	 a	disadvantage	 of	 GDNF,	 as	well	 as	 the	 lacking	 effect	 on	 numbers	 of	 striatal	 GABAergic	neurons.			
Functional	verification	of	Mfp-regulated	GDNF	expression	in	6-OHDA	lesioned	rats	The	second	animal	model	that	was	used	for	functional	verification	of	the	novel	AAV-5-GS-GDNF	construct	was	the	partial	striatal	6-OHDA	lesion	model	of	PD	28.	Here	we	could	show	robust	 improvements	 of	 the	 apomorphine-induced	 rotation	 phenotype	 already	 by	 a	single	induction	of	GDNF	expression,	which	was	performed	at	5	weeks	after	the	6-OHDA	lesion.	However,	these	animals	showed	increased	numbers	of	rotations	at	several	weeks	after	GDNF	induction,	indicating	that	the	one-time	application	of	6-OHDA	has	long-lasting	toxic	 impact,	 which	 is	 not	 fully	 counteracted	 by	 just	 one	 short	 GDNF	 induction.	 In	agreement	with	this	hypothesis,	stable	improvement	of	rotation	behaviour	and	striatal	dopamine	 content	was	 obtained	 by	 4	 cycles	 of	 GDNF	 induction,	 resulting	 in	 a	 lasting	therapeutic	effect.	These	data	confirm	our	earlier	study	with	a	previous	version	of	AAV-
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5-GS-GDNF,	where	intermitted	induction	of	GDNF	expression	rescued	striatal	dopamine	levels	and	prevented	degeneration	of	nigral	dopaminergic	neurons	to	the	same	extent	as	continuous	 GDNF	 expression	 8.	 The	moderately	 lower	 gain	 of	weight	 of	 animals	with	constitutive	GDNF	expression	as	compared	to	those	with	induced	or	no	GDNF	expression	was	 not	 significant	 in	 appropriate	 statistical	 tests	 (2-way	 ANOVA),	 but	 if	 considered	translatable	to	human	patients	might	already	be	of	serious	concern.			
Comparison	of	background	expression	and	induction	efficacy	with	other	regulated	
systems	for	GDNF	expression	It	is	not	trivial	to	quantitatively	compare	the	efficacy	of	induction	of	GDNF	expression	that	is	achieved	by	different	vector	systems,	due	to	differences	in	vector	type	and	serotype,	quality	of	vector	production	(i.e.	transducing	units	per	vector	genomes),	applied	vector	titre,	 dosage	 and	 timing	 of	 pharmacological	 control,	 duration	 of	 the	 experiment,	 etc).	However,	a	few	studies	using	regulable	GDNF	expression	in	rodent	striatum	using	an	ON-switch	for	induction	(e.g.	a	Tet-ON	rather	than	a	Tet-OFF	system,	as	in	the	latter	the	drug	is	used	to	turn	off	transgene	expression)	are	available	and	can	be	put	into	context	with	our	new	vector:	a	dual	LV	vector	using	the	Tet-ON	system	achieved	about	1000	pg	GDNF	/	mg	tissue,	but	demonstrated	high	background	of	about	250	pg	GDNF	/	mg	tissue	in	non-induced	state	29.	Early	Tet-ON	AAV	vectors	showed	no	GDNF	expression	in	non-induced	states,	but	achieved	only	very	moderate	rates	of	induction	of	about	60	pg/mg	tissue	30,	31.	A	recently	developed	AAV-Tet-ON-GDNF	vector	demonstrated	up	to	1000	pg	GDNF	/	mg	tissue	 after	 induction,	while	 background	 expression	was	 relatively	 low	 (about	 15-fold	over	background)	at	75	pg/mg	tissue	32.	In	all	these	studies,	the	inducer	doxycycline	was	applied	for	many	days	or	even	weeks	over	the	drinking	water,	it	is	thus	unknown	if	short-term	doxycycline	applications	would	 result	 in	 similar	effects.	 In	an	 alternative	 system	depending	on	stabilization	of	GDNF	fusion	proteins	coupled	to	destabilizing	domains	of	
E.coli	dihydrofolate	reductase	(DHFR),	expressed	from	a	LV	vector,	striatal	GDNF	levels	of	about	125	pg/mg	tissue	were	achieved	in	the	trimethoprim-activated	ON-state,	while	background	was	low	at	about	13	pg/mg	tissue	33.	In	yet	another	approach,	a	rapamycin-regulated	AAV	vector	expressed	GDNF	up	to	450	pg/mg	tissue,	without	any	non-induced	background,	although	by	exploiting	clinically	not	acceptable	dosages	of	rapamycin	7.		While	 all	 of	 these	 systems	 for	 regulated	 GDNF	 expression	 clearly	 have	 potential	 for	further	optimizations,	the	Mfp-regulated	vector	presented	here	represents,	at	least	for	the	time	 being,	 a	 superior	 combination	 of	 zero	 background	 expression,	 favourable	 dose-
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response	curve	to	the	inducer,	and	high-level	induction	at	clinically	acceptable	dosages	of	an	approved	small	molecule	drug.			
Mifepristone:	dose	responses	and	sex-specific	pharmacodynamics		Mifepristone	is	a	clinically	approved	drug	with	excellent	safety	profile	34,	that	is	in	use	for	emergency	 contraception	 /	 early	 pregnancy	 termination	 (in	 combination	 with	prostaglandins)	for	more	than	two	decades,	and	has	also	been	used	successfully	and	safely	in	several	off-label	situations,	i.e.	psychiatric	threats	or	Cushing	syndrome	35.	Our	study	has	 shown	 that	 a	 wide	 range	 of	 pharmacodynamics	 in	 terms	 of	 induction	 of	 GDNF	expression	 could	 be	 achieved	 in	 rodent´s	 brains.	 As	 such,	 the	 system	 has	 the	 proven	capability	to	be	able	to	adapt	levels	of	neurotrophic	factors	to	individual	situations:	for	example,	early	after	diagnosis	of	PD	and	vector	application,	high	levels	of	GDNF	might	be	most	beneficial	in	order	to	preserve	as	much	of	the	dopaminergic	projection	as	possible,	and	to	potentially	induce	a	certain	level	of	re-sprouting	of	dopaminergic	termini	in	the	basal	ganglia.	Later,	 after	having	achieved	sufficient	restoration	or	 in	case	of	any	side-effects,	 the	 dosage	 may	 be	 reduced	 to	 a	 lower	 level	 maintenance	 supply	 of	 GDNF	 or	completely	turned	off.			The	 lowest	 dosage	 of	 Mfp	 that	 induced	 GDNF	 levels	 with	 proven	 neuro-restorative	capabilities	in	our	rat	model	of	PD	(3	x	1	mg/kg,	i.p,	resulting	in	about	150	pg/mg	GDNF,	which	restored	motor	performance	 in	this	model	 in	earlier	studies	8)	corresponds	to	a	human	dose	of	3	x	0.15	mg/kg,	or	a	 total	dose	of	31.5	mg	 in	a	person	weighing	70	kg,	according	to	the	FDA	approved	normalization	to	body	surface	area	36.	The	Mfp	dose	used	for	high	level	expression	in	rats	(3	x	20	mg/kg)	corresponds	to	a	total	daily	dose	of	210	mg	 in	 humans.	 In	 clinical	 pilot	 trials	 targeting	 breast	 cancer	 37,	 meningioma	 38,	endometriosis	 39	or	uterine	 leiomyomata	 40	Mfp	has	been	 safely	administered	 in	daily	doses	of	50-200	mg	per	patient	over	several	months	,	indicating	that	the	dose	used	in	our	study	is	very	well	within	acceptable	clinical	ranges.		It	was	an	unexpected	finding	that	in	male	rat	brain	Mfp	induces	a	roughly	8-fold	lower	response	 in	 GDNF	 expression	 as	 compared	 to	 females.	 No	 literature	 is	 available	 that	quantitatively	compares	pharmacodynamics	of	Mfp	in	males	versus	females,	presumably	because	Mfp	has	been	developed	exclusively	for	use	in	women.		Mfp	is	primarily	degraded	by	cytochrome	P450	3A4	41,	the	activity	of	which	can	be	readily	modified	 by	 drugs	 like	 ketoconazole	 or	 simply	 grapefruit	 juice	 34,	 thus	 offering	
 18 
opportunities	 to	 prolong	 the	 presence	 of	 pharmacologically	 active	 levels	 without	increasing	Mfp	dosage	directly.	In	any	case,	induced	striatal	GDNF	levels	were	well	within	therapeutic	range	in	male	rat	brains	after	oral	application	of	Mfp,	indicating	that	gender	differences	 might	 be	 important	 to	 consider	 in	 further	 development	 of	 GS-GDNF	 gene	therapeutic	 applications,	but	do	not	preclude	males	 from	application	of	Mfp-regulated	neurotrophic	factor	gene	therapy.	In	addition,	our	finding	that	in	aged	rats	Mfp	apparently	has	a	higher	pharmacodynamic	potency	as	compared	to	young	animals,	probably	due	to	reduced	activity	of	cytochrome	P450	systems	in	the	liver	of	aged	individuals,	may	allow	to	make	use	of	lower	dosage	application	in	the	aged	patients	that	would	be	considered	a	target	for	GDNF	gene	therapy.		
Conclusions	We	present	an	advanced	regulated	GDNF	construct	with	zero	background	in	non-induced	state,	 high	 level	 of	 induction,	 and	well-suited	dose-response	 curve.	We	 show	 that	 this	system	 can	 be	 kept	 in	 activated	 state	 for	 extended	 periods	of	 time,	 can	 be	 readily	 re-activated	 after	 long-term	 off-status,	 and	 has	 biological	 and	 therapeutic	 effects	 in	 two	animal	models	of	disease.	Neither	regulated	nor	constitutive	GDNF	provided	therapeutic	effects	 in	 the	BACHD	model	of	Huntington´s	disease,	but	 low-frequency	 induced	GDNF	restored	motor	pathology	in	the	6-OHDA	model	of	Parkinson´s	disease.	Thus,	the	concept	of	 Mfp-regulated	 neurotrophin	 gene	 therapy	 has	 considerably	 evolved	 towards	applicability	in	clinically	well	accepted	AAV	vectors.						
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Materials	and	Methods		
Vector	construction		The	basic	properties	of	the	Mfp-regulated	“GeneSwitch	(GS)”	system	42	and	its	adaption	for	AAV	vectors-mediated	transgene	expression	in	the	brain	have	been	described	9.	For	the	 current	 study,	 we	 assembled	 the	 components	 of	 the	 GS	 system	 in	 a	 single	 vector	genome	in	different	configurations	(Fig	1A).	Vector	genome	instability	was	prevented	by	reducing	the	high	GC	nucleotide	content	of	the	genuine	GS	cDNA	by	chemical	synthesis	of	an	appropriate	cDNA.			All	constructs	evaluated	in	this	study	make	use	of	the	small	and	strictly	neuron-specific	human	 synapsin	 1	 gene	 promoter	 to	 drive	 expression	 of	 the	 GeneSwitch	 (GS)	 fusion	protein	 43.	 In	 our	 earlier	 vectors,	 other	 small	 promoters,	 i.e.	 a	 thymidine	 kinase	 (TK)	promoter	or	a	GfaABC1D	promoter	were	exploited,	in	order	to	achieve	either	neuron-	or	astrocyte-specific	 expression	 of	 GS	 8.	 However,	 both	 promoters	 turned	 out	 to	 be	 not	entirely	cell-type	specific	when	used	in	AAV	vectors	in	rodent	brain.	While	attempts	to	render	 the	small	GfaABC1D	promoter	astrocyte-specific	were	principally	 successful	by	incorporation	 of	 mir124	 target	 sequences	 44,	 the	 expression	 level	 of	 the	 resulting	constructs	was	too	low	to	be	used	for	further	developments	of	the	“GeneSwitch”	system	in	 AAVs,	 and	 was	 thus	 abandoned.	 Therefore,	 GS-GDNF	 vectors	 now	 express	 GDNF	exclusively	in	neurons.		Recombinant	 adeno-associated	 viral	 vectors	 of	 serotype	 5	 (AAV-5)	were	 prepared	 by	transient	transfection	of	vector	genome	plasmids	with	the	DP5	helper	plasmid	in	HEK293	cells,	viral	particles	were	purified	from	cell	lysates	by	iodixanol	gradient	centrifugation	and	 AVB	 affinity	 chromatography.	 After	 extensive	 dialysis	 against	 PBS	 particles	were	concentrated	on	Amicon	100	kDa	spin	concentrators	and	frozen	in	single	use	aliquots	at	-80°C.	Genome	titres	were	determined	by	qPCR	and	>98%	purity	was	confirmed	by	SDS-PAGE.		For	functional	evaluation	in	a	rat	model	of	Parkinson´s	disease	the	vector	was	produced	by	 a	 baculovirus	 packaging	 system	 in	 insect	 cells	 45.	 This	 production	 scale	 allows	 to	generate	sufficient	material	 for	clinical	application	and	was	used	here	simply	to	verify	that	this	vector	can	be	produced	at	large	scale.	
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Ethical	approval	of	animal	experimentations	All	 experimental	 animal	 procedures	 in	 rats	 were	 conducted	 according	 to	 approved	experimental	animal	licenses	(16/2074	and	11/0408)	issued	by	the	responsible	animal	welfare	 authority	 (Niedersächsisches	 Landesamt	 für	 Verbraucherschutz	 und	Lebensmittelsicherheit,	LAVES)	and	controlled	by	the	local	animal	welfare	committee	and	veterinarians	of	University	Medical	Center	Göttingen.	BACHD	mice	were	kindly	provided	by	 Dr.	 Wiliam	 Yang,	 University	 of	 California,	 Los	 Angeles,	 USA	 15.	 All	 experimental	procedures	in	BACHD	mice	were	performed	in	strict	accordance	with	Swiss	regulations	concerning	the	care	and	use	of	laboratory	animals	(veterinary	authorization	2888).		
Huntington’s	disease	model:	BACHD	mice	2	months	old	female	BACHD	mice	15	were	injected	bilaterally	with	3x10e9	vg	/	striatum	(AP:	 +1,	ML:	 +1.8,	DV:	 -3.5	mm)	with	AAV-5-GS-GDNF,	 AAV-5-GS-EGFP	 or	AAV-5-syn-GDNF	(constitutively	expressing	vector).	One	group	of	animals	received	a	higher	dose	of	AAV-5-syn-GDNF	(9x10e9	vg	/	striatum).	From	two	weeks	after	vector	injection	onwards	animals	 received	 weekly	 i.p.	 applications	 of	 Mfp	 (20	 mg/kg).	 	 Animals´	 weight	 was	recorded	 weekly.	 FVB	 mice	 (the	 genetic	 background	 of	 BACHD	 mice)	 were	 used	 as	controls	 for	 weight	 gain.	 BACHD	 and	 wild-type	 littermates	 (FVB)	 were	 trained	 on	accelerating	rotarod	for	2	days	at	9	weeks	of	age.	We	then	performed	a	3-day	accelerated	rotarod	test	on	BACHD	and	WT	littermates	and	recorded	the	average	latency	to	fall	on	each	day.	Animals	were	tested	at	14,	27,	40	and	46	weeks		of	age.		
Parkinson´s	disease	model:	partial	striatal	6-OHDA	lesion	All	surgical	operations	were	performed	under	ketamine	10%	(95	µl	per	100	g)	/	xylazin	2%	(25	µl	per	100	g)	anaesthesia	as	described8	.	Animals	received	two	injections	of	5µg	6-OHDA	in	0.02%	ascorbic	acid	into	the	left	striatum	at	the	coordinates:	AP:	+0.05,	ML:	+0.21,	DV	(from	brain	surface):		-0.5	cm	and	AP:	-0.05,	ML:	+0.38,	DV	(from	brain	surface):		-0.5	 cm.	At	3	weeks	after	6-OHDA	 injection	AAV-5-GS-GDNF	or	AAV-5-syn-GDNF	were	injected	at	a	total	titre	of	1x10e9	vg	/	striatum	at	the	same	coordinates.		
Apomorphine-induced	rotational	behaviour	Animals	 were	 injected	 intraperitoneally	 with	 0,4	 mg/kg	 apomorphine	 and	 rotation	asymmetry	 was	 monitored	 for	 60	 minutes.	 Analysis	 was	 performed	 blinded	 to	 the	
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experimental	groups.	Rotational	asymmetry	score	is	expressed	as	full	contralateral	body	turns/hour.				
Quantification	of	GDNF,	dopamine,	DOPAC	and	HVA	Striatal	samples	for	GDNF	ELISA	were	rapidly	collected	on	dry	ice.	For	all	experiments	shown	 in	 figures	 1,	 2,	 3	 and	 4,	 the	 whole	 striatum	 was	 used	 as	 one	 sample.	 For	experiments	shown	in	figure	6	C	and	D,	each	striatum	was	divided	into	two	equal	parts,	one	 being	 used	 for	 GDNF	 ELISA,	 the	 other	 for	 HPLC	 to	 determine	 dopamine	 and	metabolites.	Samples	were	stored	at	-800C	until	analysis.	The	GDNF	ELISA	was	performed	following	the	manufacturer´s	instructions	(Promega,	cat.	Nr.:	G7621).	Samples	were	lysed	using	a	Precellys	homogenizer	with	beads	in	buffer	consisting	137mM	NaCl,	20mM	Tris	(pH	8.0),	1%	Nonidet	P40,	10%	glycerol	and	protease	inhibitor	cocktail	(Complete	mini,	Roche).	GDNF	levels	are	expressed	in	pg/mg	tissue	throughout	the	text.	For	comparison	with	data	from	other	studies	we	used	a	conversion	of	1	pg/mg	tissue	=	6	pg/mg	protein.	Dopamine	 and	 its	 metabolites	 DOPAC	 and	 HVA	 were	 quantified	 by	 HPLC	 with	electrochemical	detection	exactly	as	described	8.		
Mifepristone	application	and	quantification	For	 intraperitoneal	 (i.p.)	 injections	 in	 rats	 the	synthetic	 steroid	 (Sigma	#	M8046)	was	diluted	in	DMSO;	control	animals	received	only	DMSO.	For	i.p.	injections	in	mice	Mfp	was	suspended	 in	 sesame	 oil.	 For	 oral	 administration	 Mfp	 was	 suspended	 in	 aquous	suspension	vehicle	(ASV)	consisting	of		0.9%	NaCl,	(w/v),	0.5%	carboxymethyl-cellulose	MW	250.000	(w/v),	0.4%	polysorbate	80	(v/v),	0.9%benzyl	alcohol	(v/v).		For	quantification	of	mifepristone	from	plasma	samples	a	UPLC-MS/MS	method	with	a	stable	isotope	labelled	D3-mifepristone	as	internal	standard	(IS)	was	used.	Preparation	of	 Calibrators,	 quality	 controls	 and	 samples	 were	 performed	 by	 adding	 acetonitrile	containing	IS	D3-mifepristone.	After	vigorous	vortexing	and	centrifugation,	supernatant	was	placed	into	the	autosampler	for	injection.	All	 experiments	 were	 conducted	 using	 a	 triple	 quadrupole	 mass	 spectrometric	instrument	(Xevo	TQS;	Fa	Waters)	equipped	with	an	electrospray	interface	(ESI)	operated	in	positive	ion	mode.	The	analytes	were	fragmented	using	argon	5.0	as	collision	gas	and	the	optimal	MRM	transition	was	monitored.	The	data	were	collected	and	processed	using	MassLynx	 4.1	 software.	 All	 calculations	 were	 based	 on	 peak	 area	 ratios	 of	 the	 given	mifepristone	 and	 the	 stable	 isotope	 labelled	 D3-mifepristone.	 For	 quantitation,	 the	
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following	MRM	transitions	were	used:	m/z	430/134	(quantifier)	for	mifepristone,	m/z	433/137	for	internal	standard	(IS).	The	MRM	transition	430/372	was	used	as	qualifier.	The	chromatographic	separation	was	performed	within	3	minutes	on	a	BEH	Shield	RP18	column	(100	mm	×	2.1	mm	i.d.,	1.7	µm	particle).	1%	acetic	acid	as	mobile	phase	A	and	acetonitrile	 as	 mobile	 phase	 B	 were	 used	 at	 a	 flow	 rate	 of	 0.4	 mL/min.	 The	 column	temperature	was	set	to	45	°C	and	the	injection	volume	was	7	µL.	A	sharp	linear	gradient	from	30%	B	0.3	min	to	75%	within	1.0	minute	was	performed.			
Statistical	analysis	Experimental	data	were	analysed	for	statistically	significant	differences	between	groups	by	1-way	or	2-way	ANOVA	with	Tukey´s	or	Bonferroni´s	post	hoc	test´s,	or	in	pairwise	comparisons	 by	 unpaired,	 one-	 or	 two-tailed	 T-test	 (as	 appropriate),	 given	 a	 normal	distribution	of	values	with	similar	variances.	Statistical	powers	of	all	such	comparisons	were	 analysed	 by	 G*Power3.1	 46	 with	 the	 following	 settings:	 test	 family	 =	 t-tests;	statistical	 tests	 =	 difference	 of	 means	 between	 2	 independent	 groups;	 type	 of	 power	analysis	=	post	hoc;	effect	size	d	computed	from	means	and	standard	deviations	of	groups	to	compare;	α	error	probability	=	0.05;	with	given	sample	sizes	the	power	of	the	statistical	assessment	was	computed	as	(1	–	ß	error	probability).	A	reasonable	statistical	power	of	the	respective	statistical	analysis	can	be	assumed	at	1	–	ß	error	probability	>	0.8.		
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Figures	and	legends	
	
	
	
Figure	 1:	 Development	 of	 a	 high	 induction,	 low	 background	 mifepristone-
controlled	AAV	vector	(A)	Vector	genomes	as	described	in	this	study.		(B)	Time	scale	of	experiments	shown	in	panel	(C).		
 24 
(C)	GDNF	levels	in	striatum	as	measured	by	ELISA,	in	pg/mg	tissue	±	SD.	Groups	with	3x	i.p.	application	of	Mfp	are	labeled	(Mfp	+,	solid	bars),	groups	with	3x	i.p.	DMSO	application	are	labelled	(Mfp	-,	hatched	bars).	ITR	=	inverted	terminal	repeat	from	AAV-2;	GDNF	=	glial	cell	line	derived	neurotrophic	factor;	WPRE	=	woodchuck	hepatitis	virus	posttranscriptional	regulatory	element;	BGH	=	bovine	growth	hormone	polyadenylation	site;	SV40	=	 simian	virus	40	polyadenylation	site;	Int-a	and	Int-b	=	synthetic	introns;	GS	=	fusion	protein	consisting	of	Gal4	DNA	binding	domain,	truncated	human	progesterone	receptor	and	human	p65	transactivation	domain;	hSyn	=	420	bp	fragment	of	human	synapsin	1	gene	promoter;	TB	=	synthetic	transcription	blocker	 47;	 UAS-TATA	=	minimal	 TATA	promoter	with	 6	 upstream	Gal4	 binding	 sites;	EGFP	 	 enhanced	 green	 fluorescent	 protein;	 HtH	 =	 expression	 cassettes	 for	 GS	 and	GDNF/EGFP	 in	 head-to-head	 configuration;	 HtT	 =	 expression	 cassettes	 for	 GS	 and	GDNF/EGFP	in	head-to-tail	configuration;	Mfp	=	mifepristone;	*	=	p	<	0.05,		***	=	p	<	0.001	in	pairwise	comparisons	of	groups	with	normal	distribution	and	similar	variance	by	non-paired,	 two-tailed	T-tests;	n.s.	=	no	significant	difference.	Statistical	power	P=	(1-ß	err	prob)	>	0.9	for	each	tested	condition.	N	=	7	animals	for	each	group.																	
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Figure	 2:	 Background-free	 Mfp-controlled	 GDNF	 expression	 depending	 on	 viral	
titre	and	serotype	(A)	Time	scale	of	experiments	shown	in	panel	(B).		(B)	Striatal	GDNF	levels	in	pg/mg	tissue	±	SD	as	achieved	by	AAV-5-GS-GDNF	or	AAV-5-GS-EGFP	at	titres	of	3x109	vg/striatum	or	1x109	vg/striatum,	determined	at	7	days	or	28	days	after	Mfp	application	of	20	mg/kg	on	three	consecutive	days.	Solid	bars	=	application	of	Mfp,	hatched/white	bars	=	application	of	DMSO.	**	p<	0.01,	*	p	<	0.05;	for	statistical	powers	see	text.		(C)	Decay	kinetics	of	striatal	GDNF	after	application	of	20	mg/kg	Mfp	on	three	consecutive	days.	GDNF	levels	in	pg/mg	tissue	±	SD	after	injection	of	1x109	vg/striatum	of	AAV-5-GS-GDNF.	***	p	<	0.001,	power	(1-ß	err	prob)	=	0.99;	*	p	<	0.05,	power	(1-ß	err	prob)	=	0.77.	(D)	Striatal	GDNF	levels	in	pg/mg	tissue	±	SD	as	achieved	by	different	titres	of	AAV-1/2-GS-GDNF,	measured	at	7	days	after	Mfp	application	(20	mg/kg	on	three	consecutive	days).	Solid	bars	=	application	of	Mfp,	hatched/white	bars	=	application	of	DMSO.	***	p<	0.01,	power	(1-ß	err	prob)	>	0.93;	*	p	<	0.05;	power	(1-ß	err	prob)	=	0.77.		All	vectors	used	in	head-to-tail	(HtT)	configuration.	Mfp	+	=	i.p.	application	of	20	mg/kg	Mfp	on	3	consecutive	days;	Mfp	-	=	i.p.	application	of	DMSO	on	3	consecutive	days;	DPM	=	days	post	Mfp	application;	tissue	for	GDNF	ELISA	was	isolated	at	the	indicated	times	after	the	first	Mfp	application.		Statistics	 by	 pairwise	 comparisons	 of	 groups	 with	 normal	 distribution	 and	 similar	variance	by	non-paired,	two-tailed	T-tests.	n.s.	=	no	significant	difference.	N	=	7	animals	for	each	group.												
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Figure	3:	Dose	responses	to	i.p.	or	oral	Mfp	application	(A)	Time	scale	of	experiments	for	application	of	Mfp	on	three	consecutive	days	or	on	one	day	only.		(B)	 Striatal	 GDNF	 levels	 in	 pg/mg	 tissue	 ±	 SD	 achieved	 by	 either	 i.p.	 application	 of	different	doses	of	Mfp,	dissolved	in	DMSO,	or	by	oral	application	of	different	doses	of	Mfp	suspended	 in	 an	 aqueous	 suspending	 vehicle	 (ASV).	 Mfp	 was	 either	 given	 on	 three	consecutive	days	(3x),	on	one	day	(1x)	or	not	at	all	(0x).	The	dose	applied	per	day	is	given	in	mg/kg.	*	=	p	<	0.05,		***	=	p	<	0.001	in	pairwise	comparisons	of	groups	with	normal	distribution	and	similar	variance	by	non-paired,	two-tailed	T-tests;	n.s.	=	no	significant	difference.	N	=	7	animals	for	each	group.	Power	(1-ß	err	prob)	=	1	for	all	conditions	shown,	except	for	the	difference	between	3x10	mg/kg	i.p	and	3x5	mg/kg	i.p.,	where	power	(1-ß	err	prob)	=	0.72.	
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Figure	4:	Sex-dependent	induction	of	GDNF	expression	in	rodent	brain.	(A)	Striatal	GDNF	levels	in	pg/mg	tissue	±	SD	after	i.p.	or	oral	application	of	Mfp	in	female	(F)	or	male	(M)	rats.	*	=	p	<	0.05	(power	(1-ß	err	prob)	=	0.7;		***	=	p	<	0.001	(power	(1-ß	 err	 prob)	 =	 0.99)	 in	 pairwise	 comparisons	 of	 groups	with	 normal	 distribution	 and	similar	variance	by	non-paired,	two-tailed	T-tests.	N	=	7	animals	for	each	group	(B)	Time	scale	of	experiments	shown	in	panel	(C).		(C)	Plasma	Mfp	levels	in	ng/ml	±	SD	after	application	of	Mfp	(	20	mg/kg,	i.p).	as	outlined	in	panel	(B).	Mfp	was	injected	at	time	points	0,	24	and	48	hours,	plasma	samples	were	prepared	at	time	points	1,	25,	49,	52,	66,	72	and	96	hours.	Plasma	Mfp	levels	are	shown	
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for	females	as	grey	bars	and	for	males	as	black	bars.	Satistical	analysis	by	2-Way	ANOVA	with	Bonferroni´s	post	hoc	test,	*	=	p<0.05	(1-ß	err	prob)	=	0.99	N	=	5	animals	per	group.																															
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Figure	 5:	 Long-term	 activation	 of	 GDNF	 expression	 in	 the	 BACHD	 model	 of	
Huntington´s	disease	(A)	Time	scale	of	experiments	shown	in	(B	-	I)	(B	 -	 E)	 Histological	 assessment	 of	 GDNF	 expression	 by	 immunohistochemistry	 at	 the	endpoint	of	the	study	at	47	weeks	of	age.	Representative	brain	sections	at	the	anterior-posterior	level	of	the	striatum	stained	for	GDNF	are	shown	for	BACHD	mice	injected	with	(B)	9x109	vg	AAV-5-syn-GDNF	(continuous	expression,	high	titre),	(C)	3x109	vg	AAV-5-
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syn-GDNF	(continuous	expression,	low	titre),	(D)	3x109	vg	AAV-5-GS-GDNF	and	treated	with	vehicle	and	(E)	3x109	vg	AAV-5-GS-GDNF	and	treated	with	Mfp	weekly.		(F	-	G)	Weight	of	animals	was	recorded	weekly	from	9	to	47	weeks	of	age.	(F)	Comparison	of	BACHD	mice	injected	with	AAV-5-GS-EGFP	and	treated	with	Mfp	(upper	row	of	data)	with	BACHD	mice	injected	with	AAV-5-syn-GDNF	and	treated	with	vehicle	(middle	row	of	data)	and	with	FVB	mice	injected	with	AAV-5-GS-EGFP	and	treated	with	Mfp	(lower	row	of	data).	(G)	Comparison	of	BACHD	mice	injected	with	AAV-5-GS-GDNF	and	treated	with	vehicle	(upper	row	of	data)	with	BACHD	mice	injected	with	AAV-5-GS-GDNF	and	treated	with	Mfp	 (middle	 row	 of	 data)	 and	with	 FVB	mice	 injected	with	 AAV-5-GS-EGFP	 and	treated	with	Mfp	(lower	row	of	data).	Statistical	analysis	was	performed	by	2-way	ANOVA	with	Bonferroni	post-tests,	significance	levels	of	differences	between	groups	at	individual	time	points	are	shown	between	the	respective	curves.	*	=	p	<	0.05,	**	=	p	<	0.01,	***	=	p	<	0.001;	Numbers	of	animals	in	each	group	are	outlined	besides	the	curves.	Power	(1-ß	err	prob)	>	0.9	for	each	statistically	significant	difference.		(H,	 I)	Motoric	 capabilities	were	 assessed	 at	 9,	 14,	 27,	 40	 and	 46	weeks	 of	 age	 on	 the	accelerating	rotarod	and	are	shown	as	the	time	to	fall	for	FVB	control	mice	injected	with	AAV-5-GS-GDNF	(+	Mfp),	and	BACHD	mice	injected	with	AAV-5-syn-GDNF	at	high	or	low	titre,	or	AAV-5-GS-EGFP	(+Mfp)	in	panel	(H),	and	for	BACHD	mice	injected	with	AAV-5-GS-GDNF	 (+	 or	 -	 Mfp)	 and	 AAV-5-GS-EGFP	 (+	 Mfp)	 in	 panel	 (I).	 These	 groups	 were	analysed	by	ANCOVA	(analysis	of	co-variance)	in	order	to	detect	statistically	significant	differences	 of	 GDNF	 expression	 on	 rotarod	 performance	 independent	 from	 GDNF´s	influence	on	body	weight	gain,	but	did	not	reveal	any	such	effects	on	a	significant	level.			
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Figure	6:	Restoration	of	motor	impairments	in	the	6-OHDA	model	of	Parkinson´s	
disease.	A)	 Time	 scale	 of	 experiments	 shown	 in	 panel	 (B,	 C,	 D).	 Apo	 =	 apomorphine-induced	rotations;	6-OHDA	=	striatal	6-OHDA	injection;	AAV	=	striatal	AAV	injection;	Mfp	=	 i.p.	
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application	 of	 mifepristone;	 ELISA	 =	 quantification	 of	 striatal	 GDNF	 levels;	 HPLC	 =	quantification	of	striatal	dopamine,	DPOPAC	and	HVA	levels.	Animals	received	Mfp	either	at	5	weeks,	or	at	5,	10,	15	and	20	weeks	and	once	again	at	45	weeks	after	the	6-OHDA	lesion.	B)	Apomorphine-induced	 rotation	behaviour	 in	 rats	 injected	with	 constitutively	GDNF	expressing	vector	(white	bars),	in	rats	injected	with	GS-GDNF	but	receiving	only	vehicle	(black	bars),	in	rats	injected	with	GS-GDNF	and	one	induction	of	GDNF	expression	by	Mfp	(dark	gray	bars),	and	in	rats	injected	with	GS-GDNF	and	three	inductions	by	Mfp	(light	gray	bars),	as	determined	at	0,	2,	7,	10,	12,	15,	18,	21,	24,	27	and	31	weeks	after	6-OHDA	lesion.	The	number	of	contralateral	rotations	per	hour	is	shown	as	mean	+/-	SD.	Statistical	analysis	by	1-way	ANOVA	with	Tukey´s	post	hoc	test.	*	p	<	0.05;	***	p	<	0.001;	n.s.	=	not	significant.	Power	(1-ß	err	prob)	>	0.98	for	all	shown	comparisons.	N	=	5	-	7	animals	per	group	at	the	latest	time	point	of	the	experiment.	C)	 Re-application	 of	 Mfp	 at	 week	 45	 after	 6-OHDA	 in	 animals	 of	 the	 group	 that	 had	received	4	inductions	of	GDNF	expression	at	weeks	5,	10,	15	and	20.	Striata	were	collected	one	 week	 after	 Mfp	 application,	 the	 amounts	 of	 GDNF	 detected	 in	 ipsilateral	 and	contralateral	 striatum	of	 all	 groups	 is	 shown	as	 pg	GDNf	 /	mg	 tissue	 ±	 SD.	 Statistical	analysis	by	1-way	ANOVA	with	Tukey´s	post	hoc	test.	***	p	<	0.001;	n.s.	=	not	significant.	Power	(1-ß	err	prob)	>	0.98	for	all	shown	comparisons.	N	=	5	-7	animals	per	group.	D)	 Determination	 of	 dopamine,	 3,4-dihydroxyphenylacetic	 acid	 (DOPAC)	 and	homovanillic	 acid	 (HVA)	 in	 brains	 of	 animals	 at	 week	 46	 after	 6-OHDA.	 Amounts	 of	neurotransmitter	and	metabolites	are	shown	in	ng/mg	tissue	±	SD.	Statistical	analysis	by	1-way	ANOVA	with	Tukey´s	post	hoc	test.	*	p	<	0.05;	**	p	<	0.01;	***	p	<	0.001;	n.s.	=	not	significant.	N	=	5	-	7	animals	per	group.		White	bars	=	AAV-syn-GDNF,	constitutive	GDNF	expression	(const.	GDNF);	black	bars	=	AAV-GS-GDNF,	without	any	application	of	mifepristone	(-	Mfp);	dark	gray	bars	=	AAV-GS-GDNF,	with	one	application	of	Mfp	at	week	5	after	6-OHDA	(1x	Mfp);	 light	gray	bars	=	AAV-GS-GDNF,	with	4	applications	of	Mfp	at	weeks	5,	10,	15	and	20	(4x	Mfp)	plus	one	application	 of	Mfp	 at	week	 45	 (4x	 +	 1x	Mfp);	 hached	 bars	 in	 (D)	 =	 DA,	 DOPAC,	 HVA	amounts	 in	 	 contralateral	 striata.	 Quantification	 of	 GDNF	 and	 DA/DOPAC/HVA	 was	performed	from	tissue	samples	of	the	same	animals,	by	using	50%	of	each	striatum	for	ELISA	or	HPLC,	respectively.	
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